## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($217.69)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 1)

**1. AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts**
- Source: ts2.tech | 20251215T200304 | Somewhat-Bullish | Relevance: 100%
- Bank of America Securities recently cut its price target for AbbVie (ABBV) to $233, maintaining a Neutral rating, citing a "pipeline-light" 2026 and concerns that the stock's current premium multiple may limit further valuation expansion. Despite this, other firms like HSBC and Morgan Stanley remain optimistic, raising their price targets due to strong execution, earnings momentum, and the continued growth of immunology blockbusters Skyrizi and Rinvoq. Investors are currently balancing strong fundamentals—including a recent dividend increase and significant revenue growth—with the need for clearer visibility into future growth drivers beyond the current bestsellers.

**2. AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025**
- Source: ts2.tech | 20251214T213642 | Bullish | Relevance: 100%
- AbbVie (NYSE: ABBV) heads into December 15, 2025, with strong performance, bolstered by analyst upgrades from HSBC and Morgan Stanley, and robust growth in Skyrizi and Rinvoq which are offsetting Humira erosion. The company also announced a 5.5% dividend increase, and positive pipeline developments in neuroscience and oncology are building further long-term optionality. Despite these positives, investors are monitoring risks such as policy uncertainty, aesthetics business sensitivity, and ongoing legal disputes.

**3. AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251213T032045 | Neutral | Relevance: 100%
- AbbVie Inc. (NYSE: ABBV) experienced a modest decline on December 12, 2025, both during regular trading hours and in after-hours, mirroring a broader market retreat. Key movements included a raised price target from Morgan Stanley to $269, alongside a cautionary note from Zacks regarding the stock slipping below its 50-day moving average and downward EPS estimate revisions. Investors are encouraged to watch upcoming macro-economic data, healthcare policy narratives, technical levels, and dividend schedules as the market approaches the next regular session on Monday, December 15, 2025.

**4. AbbVie price target lowered to $233 from $248 at BofA**
- Source: Yahoo Finance | 20251216T143734 | Bearish | Relevance: 100%
- BofA has reduced its price target for AbbVie (ABBV) shares to $233 from $248, while maintaining a Neutral rating. The adjustment reflects a shift in valuation basis to FY27 estimates, considering AbbVie's growth potential within its peer group alongside a premium multiple and limited late-stage pipeline catalysts.

**5. Park National Corp OH Decreases Stock Holdings in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251216T123359 | Somewhat-Bullish | Relevance: 100%
- Park National Corp OH reduced its stake in AbbVie Inc. by 6.0% in the third quarter, selling 7,072 shares, but still holds 110,555 shares valued at $25.6 million. This reduction comes after AbbVie exceeded Q3 earnings expectations with an EPS of $1.86 and revenue of $15.78 billion, and announced an increased quarterly dividend of $1.73 per share. Despite the stock decrease by this particular firm, other major institutional investors, such as Norges Bank and Laurel Wealth Advisors LLC, significantly increased their holdings in AbbVie during the same period.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +5.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.40 indicates undervaluation relative to growth. Forward P/E 16.0x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $402.0B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.40 |
| Forward P/E | 16.0 |
| Current P/E | 21.4 |
| YoY Growth | 34.0% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -2.4% to 2.6% (+5.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.4pp (needs >3.0% for momentum thesis). MRS_5 at 2.8% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 52. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.59% (CS: 57) | Neutral |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | -0.44 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.001x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $227.45
- **Stop Loss:** $217.69 (4.3% risk)
- **Target:** $237.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 122
- **Position Value:** $27,748.90
- **Portfolio %:** 27.75%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*